| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000103262979 |
| Molecular Weight (Da) | 314 |
| SMILES | c1ccc(COc2nn(Cc3ccccc3)c3ccccc23)cc1 |
| Molecular Formula | C21N2O1 |
| Action | Agonist |
| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000103262979 |
| Molecular Weight (Da) | 314 |
| SMILES | c1ccc(COc2nn(Cc3ccccc3)c3ccccc23)cc1 |
| Molecular Formula | C21N2O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000103262979 |
| Molar Refractivity | 97.198 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 24 |
| LogP | 5.039 |
| Activity (Ki) in nM | 2570.4 |
| Polar Surface Area (PSA) | 27.05 |
| Pharmacokinetic Properties | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000103262979 |
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Oatp2b1 inhibitor | - |
| Oatp1b1 inhibitor | + |
| Oatp1b3 inhibitor | + |
| Mate1 inhibitor | - |
| Oct2 inhibitor | + |
| Bsep inhibitor | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.067 |
| Pharmacokinetic Properties | |
|---|---|
| Number of aromatic heavy atoms | 21 |
| Fraction csp3 | 0.1 |
| Ilogp | 3.2 |
| Xlogp3 | 4.96 |
| Wlogp | 4.51 |
| Mlogp | 4.45 |
| Silicos-it log p | 4.3 |
| Consensus log p | 4.28 |
| Esol log s | -5.23 |
| Esol solubility (mg/ml) | 0.00185 |
| Esol solubility (mol/l) | 0.00000587 |
| Esol class | Moderately |
| Ali log s | -5.27 |
| Ali solubility (mg/ml) | 0.0017 |
| Ali solubility (mol/l) | 0.00000542 |
| Ali class | Moderately |
| Silicos-it logsw | -7.65 |
| Silicos-it solubility (mg/ml) | 0.00000702 |
| Silicos-it solubility (mol/l) | 2.23E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.7 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 2.82 |
| Pharmacokinetic Properties | |
|---|---|
| Logs | -5.788 |
| Logd | 4.416 |
| Logp | 5 |
| F (20%) | 0.965 |
| F (30%) | 0.005 |
| Mdck | - |
| Ppb | 98.95% |
| Vdss | 0.945 |
| Fu | 1.22% |
| Cyp1a2-inh | 0.941 |
| Cyp1a2-sub | 0.179 |
| Cyp2c19-inh | 0.959 |
| Cyp2c19-sub | 0.059 |
| Cl | 12.33 |
| T12 | 0.06 |
| H-ht | 0.027 |
| Dili | 0.958 |
| Roa | 0.006 |
| Fdamdd | 0.026 |
| Skinsen | 0.269 |
| Ec | 0.003 |
| Ei | 0.143 |
| Respiratory | 0.043 |
| Bcf | 2.648 |
| Igc50 | 4.744 |
| Lc50 | 5.79 |
| Lc50dm | 5.078 |
| Nr-ar | 0.113 |
| Nr-ar-lbd | 0.038 |
| Nr-ahr | 0.353 |
| Nr-aromatase | 0.172 |
| Nr-er | 0.646 |
| Nr-er-lbd | 0.474 |
| Nr-ppar-gamma | 0.01 |
| Sr-are | 0.354 |
| Sr-atad5 | 0.029 |
| Sr-hse | 0.071 |
| Sr-mmp | 0.479 |
| Sr-p53 | 0.036 |
| Vol | 341.965 |
| Dense | 0.919 |
| Flex | 0.227 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.535 |
| Synth | 1.804 |
| Fsp3 | 0.095 |
| Mce-18 | 18 |
| Natural product-likeness | -1.003 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |